

18F-AV-1451-A24 SAP v1.0

A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD

NCT03467477

Approval date: 11 Feb 2019

---

**Protocol No. 18F-AV-1451-A24**

**A MULTICENTER SCREENING STUDY WITH FLORTAUCIPIR F 18 IN  
PATIENTS WITH EARLY SYMPTOMATIC AD; #2**


**Statistical Analysis Plan**

**Prepared for:  
Avid Radiopharmaceuticals, Inc**

**Final Version 1.0  
Date 11 Feb 2019**

**Prepared by:  
  
Chiltern International Inc.  
4000 Centre Green Way, Suite 300  
Cary, NC 27513**

**Revision History**

<b>Version</b>	<b>Date</b>	<b>Revision Author</b>	<b>Comments</b>
Draft 1.0	19 Dec 2018		Original Draft
Final 1.0	11 Feb 2019		Incorporated Avid Comments

This document is the confidential information of Avid Radiopharmaceuticals. It may not be disclosed to parties not associated with the clinical investigation or used for any purpose without the prior written consent of Avid Radiopharmaceuticals.

**SIGNATURE PAGE**

Author:

---



---

Date

Reviewed by:

---



---

Date

Approved by:

---



---

Date

Approved by:

---



---

Date

Approved by:

---



---

Date

## Table of Contents

<b>1</b>	<b>LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.....</b>	<b>5</b>
<b>2</b>	<b>INTRODUCTION .....</b>	<b>6</b>
<b>3</b>	<b>STUDY OBJECTIVES .....</b>	<b>6</b>
<b>4</b>	<b>STUDY DESIGN .....</b>	<b>6</b>
4.1	GENERAL DESIGN.....	7
4.2	DISCUSSION OF STUDY DESIGN .....	8
4.3	METHOD OF ASSIGNMENT OF SUBJECTS TO TREATMENT GROUPS .....	8
4.4	BLINDING .....	8
4.5	DETERMINATION OF SAMPLE SIZE.....	8
<b>5</b>	<b>CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED ANALYSES.....</b>	<b>8</b>
5.1	CHANGES IN THE CONDUCT OF THE STUDY .....	8
5.2	CHANGES FROM THE ANALYSES PLANNED IN THE PROTOCOL/CIP .....	8
<b>6</b>	<b>BASELINE, EFFICACY AND SAFETY EVALUATIONS.....</b>	<b>10</b>
6.1	SCHEDULE OF EVALUATIONS .....	10
6.2	TIME POINT ALGORITHMS .....	11
6.2.1	<i>Relative Day</i> .....	11
6.2.2	<i>Windows</i> .....	11
6.3	SCREENING ASSESSMENTS .....	11
6.4	EFFICACY VARIABLES .....	12
6.4.1	<i>Qualitative assessment for Flortaucipir and Diagnostic Performance</i> .....	12
6.4.2	<i>Quantitative assessment of images for Flortaucipir (SUVr based)</i> .....	12
6.4.3	<i>Increased neocortical Flortaucipir activity</i> .....	13
6.5	DRUG CONCENTRATION MEASUREMENTS AND PHARMACOKINETIC PARAMETERS .....	13
6.6	SAFETY ASSESSMENTS .....	13
6.6.1	<i>Extent of Exposure and Compliance to Study Treatment</i> .....	13
6.6.2	<i>Adverse Events</i> .....	13
6.6.3	<i>Other Observations Related to Safety</i> .....	15
6.6.3.1	<i>Vital Signs</i> .....	15
6.6.3.2	<i>Electrocardiogram (ECG)</i> .....	15
6.7	PHARMACODYNAMICS PARAMETERS .....	15
<b>7</b>	<b>STATISTICAL METHODS.....</b>	<b>15</b>
7.1	GENERAL METHODOLOGY .....	15
7.2	ADJUSTMENTS FOR COVARIATES .....	15
7.3	HANDLING OF DROPOUTS OR MISSING DATA.....	15
7.4	INTERIM ANALYSES AND DATA MONITORING.....	16
7.5	MULTI-CENTER STUDIES AND POOLING OF CENTERS .....	16
7.6	MULTIPLE COMPARISONS/MULTIPLICITY.....	16
7.7	ACTIVE-CONTROL STUDIES INTENDED TO SHOW EQUIVALENCE .....	16
7.8	EXAMINATION OF SUBGROUPS .....	16

<b>8</b>	<b>STATISTICAL ANALYSIS .....</b>	<b>16</b>
8.1	ANALYSIS POPULATIONS .....	16
8.1.1	<i>Enrolled Population</i> .....	16
8.1.2	<i>Safety Population</i> .....	16
8.1.3	<i>Efficacy Population</i> .....	16
8.2	DISPOSITION OF SUBJECTS .....	17
8.3	DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS .....	17
8.4	RELEVANT FAMILY HISTORY .....	17
8.5	DISEASE HISTORY .....	17
8.6	PREGNANCY TEST .....	18
8.7	CONCOMITANT THERAPY .....	18
8.8	MEDICAL AND SURGICAL HISTORY .....	18
8.9	ANALYSIS OF EFFICACY PARAMETERS .....	18
8.9.1	<i>Qualitative Assessment of Images</i> .....	18
8.9.2	<i>Quantitative Assessment of Images</i> .....	18
8.9.3	<i>Other Efficacy Variables</i> .....	18
8.9.3.1	Increased Neocortical Activity .....	18
8.10	ANALYSIS OF SAFETY .....	19
8.10.1	<i>Extent of Exposure and Compliance to Study Treatment</i> .....	19
8.10.1.1	Unit Conversion and Volume Calculation .....	19
8.10.2	<i>Adverse Events</i> .....	19
8.10.3	<i>Vital Signs</i> .....	20
8.10.4	<i>Electrocardiogram (ECG)</i> .....	20
8.11	PHARMACODYNAMICS .....	20
<b>9</b>	<b>COMPUTER SOFTWARE .....</b>	<b>20</b>

## 1 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

**Table 1: Abbreviations and Definitions of Terms**

Aβ	amyloid-β
AD	Alzheimer's disease
AE	adverse event
ATC	Anatomical therapeutic chemical classification
BMI	body mass index
CBB	CogState Brief Battery
CIP	Clinical investigational plan
cm	centimeters
CRO	contract research organization
DBP	diastolic blood pressure
ECG	electrocardiogram
eCRF	electronic case report form
IND	investigational new drug
IV	Intravenous
K <sub>d</sub>	dissociation constant
kg	Kilograms
max	Maximum
MBq	Megabecquerel
mCi	Millicuries
MCI	mild cognitive impairment
MedDRA	Medical Dictionary for Regulatory Activities
min	Minimum
MMSE	Mini-Mental State Examination
mSv	Millisievert
MUBADA	Multiblock barycentric discriminant analysis
n	number of subjects
nM	Nanomolar
PET	positron emission tomography
SAE	Serious adverse event
SBP	systolic blood pressure
SD	standard deviation
SOC	system organ class
SOP	standard operating procedure
SUV <sub>r</sub>	standardized uptake value ratio
TEAE	treatment-emergent adverse event
WHO	World Health Organization

## 2 INTRODUCTION

Flortaucipir F 18 ( $^{18}\text{F}$ -AV-1451) (originally named [F-18]T807 by Siemens Molecular Imaging Biomarker Research group) is a positron emitting radiopharmaceutical developed for in vivo imaging of tau protein aggregates (Xia et al., 2013). Image assessment showed tracer deposition on brain PET scans to be consistent with that expected for a tracer of aggregated tau protein. Flortaucipir ( $^{18}\text{F}$ ) initially entered the brain and was subsequently eliminated from the brain in clinically normal and amyloid negative cognitively impaired subjects, yielding only a diffuse pattern of background activity, whereas a regionally distinct gray matter distribution of increased tracer retention was observed in amyloid positive cognitively impaired subjects (Pontecorvo et al., 2017). Preliminary analyses of our Phase II longitudinal study (A05, exploratory cohort) also indicated a relationship between the level and pattern of flortaucipir uptake at baseline, and the rate of decline on cognitive tests over an 18-month period (Mintun, AAIC 2017). These results suggest that it may be possible to use flortaucipir PET scans to enrich clinical studies for subjects with a desired level of AD pathology and a more homogeneous rate of cognitive decline, thus increasing power to detect a treatment effect. Specifically, Lilly and Avid desire to conduct treatment trials at the earliest stage of AD neuropathology to maximize potential patient benefit.

Proposed Lilly AD therapeutic trials intends to target subjects with a certain distribution and density of tau neurofibrillary tangles. It is thought that patients with no tau will progress so slowly that a clinical treatment effect can not be discerned, and those with a large tau burden may not be responsive to anti-amyloid therapy as their cognitive impairment is driven primarily by tau pathology. The overarching goal of AV-1451-A24 is to test this hypothesis by pre-screening subjects with flortaucipir F 18 who have been diagnosed with suspected Alzheimer's disease and have indicated their interest to consider participation in trials such as the Lilly therapeutic clinical trials.

## 3 STUDY OBJECTIVES

The primary objective is to pre-screen subjects via a flortaucipir scan, who have objectively verified cognitive impairment and etiology diagnosed or suspected to be due to Alzheimer's disease, and have indicated their interest in participating in Lilly sponsored trials that require tau imaging for inclusion.

The secondary objective of the study is to expand the flortaucipir F 18 safety database.

## 4 STUDY DESIGN

## 4.1 General Design

Study <sup>18</sup>F-AV-1451-A24 is a multicenter screening study in subjects with early symptomatic AD (defined as prodromal AD and mild dementia due to AD).

All subjects will provide informed consent before starting any study procedures. This prescreening study targets subjects who are interested in participating in AD therapeutic clinical trials and have expressed a preliminary interest in a trial like the LMDC trial, and who are not known to have met any of the exclusion criteria for trials like LMDC based on medical history and clinical examination. However, consent for this protocol does not constitute consent for the LMDC trial or any other trials, and subjects who qualify for this protocol may still fail to qualify for trials like LMDC or other trials based on the results of this protocol or based on additional testing performed in those subsequent trials.

Screening assessments may take place over several days and will be performed within 30 days prior to flortaucipir F 18 injection. Screening assessments will include demographic information, cognitive testing, disease history, concomitant medications, vital signs, ECG and medical history. Subjects who are deemed eligible to continue will complete a flortaucipir PET scan.

A physician or a licensed/credentialed medical professional (i.e., a PET technologist, imaging center nurse or a regional equivalent) designated by the site principal investigator must assess or evaluate the subject prior to administration of flortaucipir F 18 injection to determine if they are still suitable to undergo the scan.

All subjects will receive a single IV bolus administration target dose of 370 MBq (10 mCi) of flortaucipir F 18 injection followed by saline flush. At approximately 75 minutes following injection, a continuous 30-minute brain scan will be performed.

The injection site will be observed for excessive inflammation or damage to the surrounding tissue at the injection site. Adverse events will be continuously monitored during the flortaucipir PET imaging visit. Subjects who experience an adverse event will not be discharged from the imaging center until the event has resolved or stabilized. A follow-up phone call to the subject, or informant where applicable, will be conducted within 2 or 3 business days of the imaging day, but not before 48 hours post-injection, to confirm subject well-being and to collect any new adverse events.

A physician or a licensed/credentialed medical professional (i.e., a PET technologist, imaging center nurse or a regional equivalent) designated by the site principal investigator must assess or evaluate the subject prior to discharge from the imaging center to evaluate the subject's readiness for discharge.



Subjects who meet eligibility criteria will participate in this protocol until they complete their flortaucipir PET scan, or they discontinue, withdraw consent, or if the sponsor decides to end this protocol early.

## **4.2 Discussion of Study Design**

This trial is designed to pre-screen subjects via a flortaucipir scan, who have objectively verified cognitive impairment and etiology diagnosed or suspected to be Alzheimer's disease, and have indicated their interest in participating in Lilly sponsored trials that require tau imaging for inclusion.

## **4.3 Method of Assignment of Subjects to Treatment Groups**

### **Flortaucipir F 18:**

All subjects will receive a single IV bolus administration target dose of 370 MBq (10 mCi) of flortaucipir F 18 Injection.

## **4.4 Blinding**

A blinded design is not used for this trial, because all subjects will receive the same medication.

## **4.5 Determination of Sample Size**

This is a pre-screening study that targets subjects who are interested in participating in AD therapeutic clinical trials and have expressed a preliminary interest in a trial like the LMDC trial. Therefore, approximately 500 subjects will be enrolled in this study.

# **5 CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED ANALYSES**

## **5.1 Changes in the Conduct of the Study**

There were no changes in the conduct of the study at the time of preparing this statistical analysis plan.

## **5.2 Changes from the Analyses Planned in the Protocol/CIP**

There were no changes in the analyses planned in the Protocol/CIP at the time of preparing this statistical analysis plan.

## 6 BASELINE, EFFICACY AND SAFETY EVALUATIONS

### 6.1 Schedule of Evaluations

Evaluations/Procedures	Screening Visit <sup>a</sup>	Flortaucipir F 18 Imaging Visit	End of Flortaucipir F 18 Imaging (prior to discharge)	Follow-up Phone Call
Signed Consent	X			
Demographics	X			
Medical History/Neurologic Disease History	X			
Concomitant Meds	X	X		
Vital Signs <sup>b</sup>	X			
ECG	X			
MMSE and CBB <sup>c</sup>	X			
Serum beta-hCG <sup>d</sup>	X			
Urine Pregnancy Test <sup>e</sup>		X		
flortaucipir F 18 scan		X		
Evaluation by a physician <sup>f</sup>	X	X	X	
Adverse Events	X	X	X	X
Serious Adverse Events	X	X	X	X

- Screening may take place over several days. All assessments must be performed within approximately 30 days of the <sup>18</sup>F-AV-1451 imaging session.
- Vital signs (pulse, respiratory rate, supine blood pressure). Weight will be taken at the imaging visit.
- All patients will complete the MMSE, performed using Serial-7's, followed by the CBB.
- Serum beta-hCG pregnancy test at screening for females of childbearing potential.
- For women of childbearing potential, a negative urine pregnancy test must be obtained within 24 hours prior to the flortaucipir F 18 injection.
- A physician must see the patient during screening. For the imaging visit, a physician or PI designee may evaluate the patient.

## **6.2 Time Point Algorithms**

### **6.2.1 Relative Day**

The date of first dose of study drug (flortaucipir F 18) will be considered relative day 1, and the day before the first dose of study drug will be relative day -1. Relative days will be calculated as follows only when the full assessment date is known (i.e., partial dates will have missing relative days):

For days on or after the first dose of study drug:

Date of Assessment – Date of First Dose of Study Drug + 1.

For days before the first dose of study drug:

Date of Assessment – Date of First Dose of Study Drug.

### **6.2.2 Windows**

No window algorithm is being used for this study.

## **6.3 Screening Assessments**

Screening may take place over several days. All screening assessments will be performed within 30 days prior to flortaucipir F 18 injection. Screening assessments will include:

- Informed consent for subject;
- Demographics (age, birth gender, years of education, race, ethnicity); weight/height; weight will be collected during the imaging visit.
- Medical history, concomitant medications;
- Vital Signs (pulse, respiration rate, supine blood pressure)
- An ECG will be performed to assess the subject's cardiac status. If an ECG was performed within the last 12 months of the flortaucipir (<sup>18</sup>F) PET Imaging Visit and is available for review, the ECG does not need to be repeated.
- ApoE status, if available;
- Disease history (date/months since symptom onset, date/months since diagnosis, family history of relevant neurologic disease);
- Cognitive status interview, including MMSE, performed using Serial-7's and CBB;
- A physician will see the subject during the screening visit.
- For women of childbearing potential, a negative serum pregnancy test must be obtained at the screening visit

Weight will be displayed in kilograms (kg), height will be displayed in centimeters (cm). Weights and heights recorded in alternate units will be converted to the units being displayed using standard conversion formulas. Body mass index (BMI) will be calculated as weight (kg) divided by height squared (cm<sup>2</sup>).

APOE4 Positive is any subject with at least one of their two APOE alleles as an E4 allele.

Each subject's age (years) will be calculated as the difference of the year of his/her informed consent date and the year of his/her birth.

The MMSE (Folstein et al., 1975) is a brief instrument used to assess cognitive function in elderly subjects. The instrument is divided into 2 sections. The first section measures orientation, memory, and attention. The maximum score for the first section is 21. The second section tests the ability of the subject to name objects, follow verbal and written commands, write a sentence, and copy figures. The maximum score for the second section is 9. The range for the total MMSE score is 0 to 30, the sum of each correct answer, with higher scores indicating better cognition.

The CBB will be administered to patients at screening in addition to the MMSE. The CBB is a brief (15-18 minute), computer-based cognitive test battery designed to measure psychomotor function, attention, working memory and memory (Maruff et al. 2009, 2013; Fredrickson et al. 2010; Darby et al. 2012). The CBB has been shown to be sensitive to AD-related cognitive decline in healthy older adults and in adults with amnesic MCI (Darby et al. 2002, 2012; Lim et al. 2013a, b) as well as to improvement in cognition arising from treatment with cognitive enhancing drugs (Davison et al. 2011; Jaeger et al. 2011; Nathan et al. 2013). The CBB will be administered at screening in an effort to further characterize patients enrolled in the study.

## **6.4 Efficacy Variables**

### ***6.4.1 Qualitative assessment for Flortaucipir and Diagnostic Performance***

The flortaucipir scan image will be visually interpreted. The scans will be classified as either

- Not consistent with an AD pattern ( $\tau$ AD-)
- AD pattern ( $\tau$ AD+)
- AD pattern and likely to progress ( $\tau$ AD++)

### ***6.4.2 Quantitative assessment of images for Flortaucipir (SUVr based)***

For the flortaucipir image, standard uptake value ratios (SUVr) will be calculated to estimate tau globally. SUVr will be calculated after the visual read and only on scans that

were  $\tau_{AD+}$  or  $\tau_{AD++}$ . For global assessment, a target region derived statistically with a Multiblock Barycentric Discriminant Analysis (MUBADA) method will be used.

#### ***6.4.3 Increased neocortical Flortaucipir activity***

The hemisphere and region of increased neocortical flortaucipir activity will be identified by visual read.

The hemisphere will be classified as either left or right and the region is classified as

- Anterior Lateral Temporal
- Posterior Lateral Temporal
- Occipital
- Parietal
- Precuneus
- Frontal

### **6.5 Drug Concentration Measurements and Pharmacokinetic Parameters**

No pharmacokinetic parameters or drug concentration measurements will be collected during this study.

### **6.6 Safety Assessments**

#### ***6.6.1 Extent of Exposure and Compliance to Study Treatment***

During the flortaucipir imaging session, subjects will receive a single IV bolus administration target dose of 370 MBq (10 mCi) of flortaucipir F 18 injection followed by a saline flush. At approximately 75 minutes following injection, a continuous 30-minute brain scan will begin. Exposure to study drug will be summarized using the total administered dose at the scan visit for flortaucipir F 18 injection.

#### ***6.6.2 Adverse Events***

The investigator's verbatim term of adverse events will be mapped to system organ class (SOC) and preferred terms using the current version of the Medical Dictionary for Regulatory Activities (MedDRA).

Treatment-emergent AEs (TEAEs) are undesirable experiences, signs, or symptoms that begin or worsen in intensity or frequency at the time of or after the administration of study drug at the imaging visit, and prior to the end of observation windows defined as

following: the TEAE window will be from injection of flortaucipir F 18 until 48 hours post flortaucipir F 18 injection. These will be recorded on the AE page of the electronic case report form (eCRF).

Serious AEs (SAEs) are events that result in one of the following outcomes or constitute one of the following events:

- Death
- Initial or prolonged hospitalization (other than that required by protocol; “social hospitalization” or any hospitalization for non-medical reasons does not constitute an SAE)
- A life-threatening experience (that is, immediate risk of dying)
- Persistent or significant disability/incapacity
- Congenital anomaly/birth defect
- Considered significant by the investigator for any other reason

Important medical events that may not result in death, are life-threatening, or require hospitalization may be considered serious adverse drug events when, based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

For the summarization of TEAEs by seriousness, events recorded with missing seriousness will be summarized as serious.

Investigators will be instructed to report their assessment of the potential relatedness of each AE to protocol procedure or study drug. The assessment of the relationship of an AE to the administration of the investigational product is a clinical decision based on all available information at the time of the completion of the eCRF. For the summarization of TEAEs by relationship to study drug or protocol procedure, events recorded with missing relationship will be summarized as Related.

In addition to assessing the relationship of the administration of the investigational product to AEs, an assessment is required of the severity of the event. The following classifications should be used:

*Mild:*

A mild AE is an AE, usually transient in nature and generally not interfering with normal activities.

*Moderate:*

A moderate AE is an AE that is sufficiently discomforting to interfere with normal activities.

*Severe:*

A severe AE is an AE that incapacitates the subject and prevents normal activities. Note that a severe event is not necessarily a serious event. Nor must a serious event necessarily be severe.

For the summarization of TEAEs by intensity, events recorded with missing intensity will be summarized as Severe.

### ***6.6.3 Other Observations Related to Safety***

#### ***6.6.3.1 Vital Signs***

Vital signs (pulse rate, respiratory rate, and supine blood pressure) will be taken at the screening visit. Weight will be measured, lightly clothed during the imaging visit.

#### ***6.6.3.2 Electrocardiogram (ECG)***

A resting 12-lead electrocardiogram will be recorded as part of the screening visit, unless an ECG was performed within twelve months of the flortaucipir PET Imaging Visit and is available for review.

## **6.7 Pharmacodynamics Parameters**

No pharmacodynamics parameters will be collected during this study.

## **7 STATISTICAL METHODS**

### **7.1 General Methodology**

All values will be summarized as a single group, early symptomatic AD. Frequency distributions including counts and percentages will be reported for all categorical outcomes. Summary statistics including number of subjects [N], mean, standard deviation [SD], median, quartiles, minimum and maximum values will be presented for all continuous outcomes.

All statistical analyses will be performed using SAS® version 9.3 or higher. Patient listings of all data from the eCRF as well as any derived variables will be presented.

### **7.2 Adjustments for Covariates**

Not applicable for the primary analyses.

### **7.3 Handling of Dropouts or Missing Data**



Dropout subjects will not be replaced in this study. For situations with no rules for handling missing data, the default will be no imputation.

#### **7.4 Interim Analyses and Data Monitoring**

No interim analysis or data monitoring is planned for this study

#### **7.5 Multi-center Studies and Pooling of Centers**

This study will be conducted in approximately 15 centers. The data from all centers will be pooled. The pooled data will be analyzed and presented.

#### **7.6 Multiple Comparisons/Multiplicity**

No adjustment for multiplicity will be performed in this study.

#### **7.7 Active-Control Studies Intended to Show Equivalence**

Not applicable to this study.

#### **7.8 Examination of Subgroups**

No subgroup analysis will be performed.

### **8 STATISTICAL ANALYSIS**

#### **8.1 Analysis Populations**

##### ***8.1.1 Enrolled Population***

The enrolled population will consist of all subjects who signed informed consent and have data captured in the clinical database. Disposition information will be summarized using the enrolled population.

##### ***8.1.2 Safety Population***

The safety analysis population will include all subjects who enroll in <sup>18</sup>F-AV-1451-A24 (A24) and have received at least one dose of flortaucipir F 18 injection.

All demographic, baseline and safety endpoints will use the safety population.

##### ***8.1.3 Efficacy Population***

The efficacy analysis population will include all subjects in the safety population that have a valid flortaucipir scan assessment [SUVr (quantitative) and/or visual reads (qualitative)].

Any scans deemed to be unquantifiable due to technical reasons will be excluded from SUVr related analyses.

All analyses involving imaging outcomes will be based on the efficacy population.

## **8.2 Disposition of Subjects**

The enrolled population will be represented in the disposition table. The disposition table will include a summary of the analysis populations, number of completed and discontinued subjects, and the reasons for discontinuation. All percentages will be based on the safety population.

Disposition data will be presented in a listing.

## **8.3 Demographic and Other Baseline Characteristics**

All baseline summaries will be based on the safety population.

Frequency distributions and summary statistics for demographic and baseline variables will be presented across all subjects. Key demographic and baseline characteristics to be summarized include: age, birth gender, race, ethnicity, height, weight, BMI, highest level of education, alcohol history, recreational drug use history, smoking history, MMSE, CBB (if the CBB assessment is repeated, this second CBB score will be used in the CBB summary table), and ApoE Genetic testing.

All demographic and baseline characteristics data will be presented in listings.

## **8.4 Relevant Family History**

Data from Family History CRF will be summarized in a listing.

## **8.5 Disease History**

Months since symptom onset and diagnosis will be presented in a listing for the safety population.

## **8.6 Pregnancy Test**

Data from Pregnancy Test CRF will be presented in a listing for the safety population.

## **8.7 Concomitant Therapy**

A current version of the World Health Organization (WHO) Drug Dictionary will be used to classify medications by preferred term and WHO Anatomical Therapeutic Chemical (ATC) classification of ingredients. ATC classification level 3 will be used. If level 3 is missing, then level 2 will be used. If level 2 is missing, then level 1 will be used.

All concomitant medications data will be presented in listings for the safety population.

## **8.8 Medical and Surgical History**

Medical and Surgical History will be coded using MedDRA Version 21.1. Medical and surgical history will be presented in a listing for the safety population.

## **8.9 Analysis of Efficacy Parameters**

All efficacy information as well as related data (flortaucipir PET scan information and flortaucipir PET results) will be presented in the listings.

### ***8.9.1 Qualitative Assessment of Images***

The visual read results will be categorized as  $\tau$ AD+,  $\tau$ AD++ and  $\tau$ AD-. The visual read results will be summarized by frequency distribution (count and percentage) for the efficacy population by subject eligibility and overall.

### ***8.9.2 Quantitative Assessment of Images***

The Screening MUBADA SUVR will be summarized using descriptive statistics [n, mean, SD, median, minimum and maximum values, and quartiles (25<sup>th</sup> and 75<sup>th</sup> percentile)] by visual read results ( $\tau$ AD+,  $\tau$ AD++), subject eligibility, and overall.

### ***8.9.3 Other Efficacy Variables***

#### ***8.9.3.1 Increased Neocortical Activity***

Increased neocortical flortaucipir activity by hemisphere and region will be presented in a listing.

## 8.10 Analysis of Safety

### ***8.10.1 Extent of Exposure and Compliance to Study Treatment***

The total dose administered (MBq) of Flortaucipir F 18 will be summarized using descriptive statistics. All exposure data captured on the CRF will be presented in listings for the safety population.

Because this is a study with only one bolus of study medication per imaging visit, compliance will not be summarized.

#### *8.10.1.1 Unit Conversion and Volume Calculation*

All exposure tables will display volume in MBq. Radioactive dose collected in millicuries (mCi) will be converted to MBq as follows:

$$MBq = 37 \times mCi$$

### ***8.10.2 Adverse Events***

TEAEs will be summarized by descending frequency, then alphabetically by SOC and preferred term. A subject will only be counted once per SOC and once per preferred term. Subject counts and percentages will be presented for the following summaries:

1. All TEAEs by system organ class (SOC) and preferred term;
2. All TEAEs by preferred term (in order of descending frequency);
3. All TEAEs by relationship to study drug, SOC, and preferred term;
4. All TEAEs by relationship to protocol procedure, SOC and preferred term;
5. All TEAEs by severity, SOC and preferred term
6. All Serious TEAEs by system organ class (SOC) and preferred term;
7. All TEAE leading to study termination by system organ class (SOC) and preferred term

For the summary of TEAEs by severity, if a subject has multiple events occurring in the same SOC or same preferred term, the event with the highest severity will be counted.

TEAEs by relationship to study drug and protocol procedure will be summarized as Related vs. Not Related. If a subject has multiple events occurring in the same SOC or same preferred term, the related event will be summarized.

All AE will be presented in the listings.

### ***8.10.3 Vital Signs***

All vital signs data will be presented in the listings.

### ***8.10.4 Electrocardiogram (ECG)***

All ECG data will be presented in the listings.

## **8.11 Pharmacodynamics**

No pharmacodynamics analyses are planned for this study.

## **9 COMPUTER SOFTWARE**

All analyses will be performed by Chiltern using SAS® Version 9.3 or later. All summary tables and data listings will be prepared utilizing SAS® software.

The standard operating procedures (SOPs) of Chiltern will be followed in the creation and quality control of all data displays and analyses.